A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer's Disease
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009311/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the study is to evaluate the safety and tolerability of
single-ascending intravenous (IV) infusions of BIIB076 in healthy volunteers and participants
with Alzheimer's disease (AD). A secondary objective of the study for both healthy volunteers
and participants with AD is to assess the serum pharmacokinetic(s) (PK) profile of BIIB076
after single-dose administration. Another secondary objective is to evaluate the
immunogenicity of BIIB076 in serum after single-dose administration.
提供机构：
Vivli
创建时间：
2023-09-27
